GOVX · GeoVax Labs, Inc.

This warrant inducement transaction represents a strategic capital-raising mechanism that accelerates near-term cash inflow while deferring dilution and preserving balance sheet flexibility. By offering existing warrant holders a 2:1 warrant-for-warrant exchange at a higher strike ($1.65 vs. the original $1.1877), GeoVax incentivized immediate cash exercise of 501,144 warrants — generating $595,000 in gross proceeds before fees. Critically, the new warrants are not immediately exercisable; their Initial Exercise Date is contingent upon stockholder approval, which the Company has contractually committed to secure by June 17, 2026. This creates a defined timeline for governance action and introduces execution risk: failure to obtain approval would delay or prevent exercise of the 1,002,288 New Warrant Shares. The issuance is exempt from registration under Regulation D and Section 4(a)(2), meaning the New Warrants and underlying shares carry restrictive legends and cannot be freely traded unless registered or sold under Rule 144 — adding liquidity constraints for investors. The Company also undertook affirmative obligations, including filing a Form S-1 resale registration statement within 20 days of the May 8, 2026 Closing Date and maintaining its effectiveness until all New Warrants are expired or exercised. Financially, the arrangement includes a 7.0% advisory fee to AGP on gross proceeds ($41,650) plus up to $40,000 in reimbursed legal costs, meaning net proceeds are materially reduced. For investors, this event signals management’s prioritization of near-term liquidity over immediate equity dilution, while simultaneously expanding potential future dilution contingent on both stockholder approval and future warrant exercise decisions — making it a high-materiality financing and governance event with layered timing and regulatory dependencies.